PRESS RELEASE FLSmidth & Co. A/S 23 February 2026 Copenhagen, Denmark FLSmidth & Co. A/S (FLSmidth) today announces that Qasim Abrahams has been appointed President, Products Business Line, effective immediately, succeeding Julian Soles, who will leave the company. In addition, Alanas Kraujalis is appointed interim President, Service Business Line.This announcement follows the recent appointment of Toni Laaksonen as CEO of FLSmidth. Under Toni’s leadership the company is set to leverage its strengthened fou ...

LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will ...

Akamai Guardicore Segmentation and NVIDIA BlueField integration ends the long-standing trade-off between advanced security and system performance for energy, manufacturing, and transportation sectorsCAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akamai (NASDAQ: AKAM) has announced a new solution powered by NVIDIA to protect most vital systems from increasingly sophisticated cyberattacks. By combining Akamai Guardicore Segmentation software with NVIDIA BlueField Data Processing Units (DPU), the companie ...

Core Viewpoint - Photronics, Inc. has announced a rescheduling of its earnings conference call for Q1 fiscal 2026 due to inclement weather affecting logistics, while the financial results will still be released as planned [1][2]. Group 1: Earnings Conference Call - The earnings conference call is rescheduled to Friday, February 27, 2026, at 8:30 a.m. Eastern time [1][2]. - The financial results for Q1 fiscal 2026 will be released on February 25, 2026, before the market opens [1]. - During the call, management will address questions regarding financial performance, business conditions, and industry outlook, with some responses potentially containing previously undisclosed information [2]. Group 2: Company Overview - Photronics is a leading manufacturer of photomasks for integrated circuits (IC) and flat panel displays (FPD), which are essential for transferring circuit patterns onto semiconductor wafers and FPD substrates [3]. - The company was founded in 1969 and operates 11 manufacturing facilities strategically located in Asia, Europe, and North America [3].

Core Viewpoint - Rubico Inc. has announced an agreement to acquire 100% of a Marshall Islands company that is a counterparty to a shipbuilding contract for a new medium-range oil tanker, with delivery scheduled for 2029 [1][2]. Group 1: Acquisition Details - The acquisition involves a purchase price of approximately $4.2 million for the shares of the Special Purpose Vehicle (SPV) [4]. - The transaction was approved by a special committee of independent board members, and a fairness opinion was obtained from an independent financial advisor [4]. Group 2: Financing Arrangements - The effectiveness of the shipbuilding contract is contingent upon the issuance of a customary refund guarantee and the conclusion of financing arrangements [2]. - The SPV is finalizing a lease financing agreement with ABC Financial Leasing Co., Ltd., which will cover the majority of the shipbuilding contract's price [2]. Group 3: Revenue Potential - A time charter employment has been secured with a major oil trader for the vessel, starting from its delivery for a firm duration of seven years, with an option to extend for four additional years [3]. - The total potential gross revenue backlog from this charter contract, including optional years, is estimated to be around $75 million [3]. Group 4: Company Overview - Rubico Inc. is a global provider of shipping transportation services, specializing in vessel ownership and operation [5]. - The company operates two modern, fuel-efficient Suezmax tankers and is incorporated in the Marshall Islands with executive offices in Athens, Greece [5].

Core Insights - T3 Defense Inc. has announced two senior leadership appointments to enhance execution, scalability, and long-term production reliability in the Aerospace and Defense sector [1][2] Leadership Appointments - Emil Blumer has been appointed as Chief Business Officer, responsible for growth strategy, deal flow, and market positioning, bringing over 25 years of defense industry experience [3][4] - Jordan Buchler has been appointed as Chief Executive Officer of the Manufacturing & Industrial Processing Division, focusing on expanding manufacturing throughput and standardizing processes [5][6] Experience and Responsibilities - Mr. Blumer's experience includes senior roles at Rafael Advanced Defense Systems, where he gained insights into industrial capacity and supplier readiness, which will inform T3 Defense's commercial strategy [3][4] - Mr. Buchler has over 20 years of experience in building operational systems in constrained environments, with a focus on identifying critical paths and expanding capacity in defense manufacturing [6][7] Strategic Focus - The leadership changes signal T3 Defense's commitment to enhancing the most constrained layers of the defense supply chain, operating as a federated holding company to align commercial and operational leadership [7][9] - The company aims to convert durable backlogs into repeatable production output, addressing the limitations in the industrial base that affect defense output [8][9] Company Overview - T3 Defense Inc. is a federated holding company focused on acquiring and operating mission-critical defense businesses within long-cycle national security programs, targeting areas where strategic value and execution are critical [9]

Head Office : 4 allée de l'Arche, 92400 Courbevoie, FranceTel : + 33 (0) 1 78 15 00 00 – www.nexans.coma French Société Anonyme with a share capital of € 43,744,779 – R.C.S. Nanterre 393 525 852 – Id VAT FR 74 393 525 852 Disclosure of trading in own shares From February 16, 2026 to February 20, 2026 Issuer : Nexans Category : treasury shares Pursuant to applicable law on share buybacks, Nexans declares the following purchases of its own shares from F ...

Group 1: Kraig Biocraft Laboratories - Kraig Biocraft Laboratories' recombinant spider silk technology has gained significant visibility by being featured on the cover of National Geographic's March 2026 issue, which could lead to increased investor interest [2][4] - The company is set to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, aiming for a production target of up to 10 metric tons of cocoons per month starting in March 2026 [5] - Scientific validation published in the Proceedings of the National Academy of Sciences confirms that Kraig's fibers are tougher than conventional silk and comparable to native spider dragline silk [5] - If successful, Kraig could become the second company to achieve sustained commercial production from a transgenic animal platform, a milestone previously associated with ATryn [6] - Investors are closely monitoring for initial deliveries to global brand partners in luxury fashion and performance sportswear, which could transition Kraig from a research-focused entity to a specialty materials platform [8] Group 2: Gilead Sciences and Arcellx - Gilead Sciences has announced a definitive agreement to acquire Arcellx for $115 per share in cash, plus a $5 contingent value right, representing an implied equity value of approximately $7.8 billion [9] - The acquisition provides Gilead with full control of anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma, with the FDA accepting the BLA and a PDUFA action date set for December 23, 2026 [10] - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in enhancing Gilead's oncology and inflammation capabilities [11] Group 3: ImmunityBio - ImmunityBio reported approximately $113 million in net product revenue for ANKTIVA in 2025, reflecting a 700% year-over-year growth [13] - The company also experienced a 750% increase in unit sales volume and expanded regulatory authorization across 33 countries [13] - ImmunityBio is positioning ANKTIVA as a backbone immunotherapy platform with ongoing randomized trials and long-term patent protection extending beyond 2035 [15] Group 4: Getty Images and Shutterstock - Getty Images and Shutterstock received unconditional antitrust clearance from the U.S. Department of Justice for their proposed merger, which aims to strengthen their financial foundation and competitive positioning in the visual content market [16][17]

Core Insights - LiveOne has launched its award-winning app on VIZIO smart TVs, providing users with free 24/7 access to its music service [1][2] - The app enhances LiveOne's distribution, reaching over 1.3 billion monthly active users across various platforms [4] Company Overview - LiveOne is a creator-first music, entertainment, and technology platform headquartered in Los Angeles, CA, focusing on delivering premium experiences through memberships and live events [2] - The company operates several subsidiaries, including Slacker, PodcastOne, and LiveXLive, and offers its services across multiple devices and platforms [2] Product Features - The LiveOne app allows users to listen to hundreds of curated music stations across more than 30 genres and create custom stations based on their preferences [5] - Users receive personalized recommendations for music and podcasts, access popular podcast shows, and can watch live streaming performances and interviews [5] - The app also offers curated video content and subscription tiers that provide additional features such as ad-free listening and offline playback [5] Strategic Partnerships - LiveOne anticipates forming at least two additional Fortune 250 B2B partnerships by the end of the year, further expanding its market reach [4]

Core Viewpoint - INmune Bio Inc. is advancing its clinical development of XPro1595 for early Alzheimer's disease, with a webinar scheduled to discuss the registrational pathway and recent trial results [1][2]. Group 1: Clinical Development - The Phase 2 MINDFuL trial has been completed, and feedback from the FDA supports moving to a registrational study for Alzheimer's patients with inflammation biomarkers [2]. - XPro1595 is a next-generation selective soluble TNF inhibitor aimed at restoring immune homeostasis in the brain without affecting transmembrane TNF or TNF receptors [3][10]. Group 2: Webinar Details - The webinar will cover three main topics: results from the MINDFuL trial, the design of the registrational study, and the strategic roadmap to Phase 3, including global partnership opportunities [3][4][5]. - Featured speakers include Dr. Michael Woodward and Dr. Sharon Cohen, both recognized experts in Alzheimer's disease research [6]. Group 3: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms: CORDStrom™, XPro™, and INKmune® [11].